KalVista Pharmaceuticals Inc. Insider Trading

KALV

Last 12 months

Insiders sold $3.38M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Development Officer Christopher Yea sold 905K on May 27, 13% of their stake, outside a plan. The last open-market buy by an executive or director was in Oct 2020.

Net open-market

−$3.38M

0 buys · 37 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Oct 2020

Oct 30, 2020

Get an email when KALV's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 27	Christopher Yea Chief Development Officer	SoldNo plan	33,800	$26.78	905K	13%	Form 4
May 26	Paul K. Audhya Chief Medical Officer	SoldNo plan	2,239	$26.78	60K	1.5%	Form 4
May 26	Nicole Sweeny Chief Commercial Officer	SoldNo plan	1,489	$26.78	40K	2.4%	Form 4
May 26	Christopher Yea Chief Development Officer	SoldNo plan	1,966	$26.78	53K	0.8%	Form 4
May 22	Paul K. Audhya Chief Medical Officer	SoldNo plan	2,685	$26.78	72K	1.8%	Form 4
May 22	Nicole Sweeny Chief Commercial Officer	SoldNo plan	1,861	$26.78	50K	3.2%	Form 4
May 22	Brian Piekos Chief Financial Officer	SoldNo plan	1,489	$26.78	40K	6.4%	Form 4
May 22	Christopher Yea Chief Development Officer	SoldNo plan	2,358	$26.78	63K	1.0%	Form 4
May 22	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	10,926	$26.78	293K	2.2%	Form 4
May 18	Paul K. Audhya Chief Medical Officer	SoldNo plan	1,032	$26.76	28K	0.7%	Form 4
May 18	Christopher Yea Chief Development Officer	SoldNo plan	1,108	$26.76	30K	0.5%	Form 4
May 18	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	1,129	$26.76	30K	0.2%	Form 4
May 12	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	3,322	$26.71	89K	0.7%	Form 4
Apr 17	Paul K. Audhya Chief Medical Officer	SoldNo plan	2,686	$20.22	54K	1.8%	Form 4
Apr 17	Nicole Sweeny Chief Commercial Officer	SoldNo plan	1,862	$20.22	38K	3.5%	Form 4
Apr 17	Brian Piekos Chief Financial Officer	SoldNo plan	1,862	$20.22	38K	9.3%	Form 4
Apr 17	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	9,550	$20.22	193K	2.0%	Form 4
Mar 25 – 26	Venrock Healthcare Capital Partners EG, L.p. Large holder	SoldNo plan 5 parts	214,631	$17.20 average	$3.69M	4.0%	Form 4
Mar 9	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	6,693	$16.08	108K	1.5%	Form 4
Feb 23	Paul K. Audhya Chief Medical Officer	SoldNo plan	5,354	$15.57	83K	3.7%	Form 4
Feb 23	Nicole Sweeny Chief Commercial Officer	SoldNo plan	3,975	$15.57	62K	7.8%	Form 4
Feb 23	Brian Piekos Chief Financial Officer	SoldNo plan	1,767	$15.57	28K	11%	Form 4
Feb 23	Christopher Yea Chief Development Officer	SoldNo plan	4,347	$15.57	68K	1.9%	Form 4
Feb 23	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	10,034	$15.57	156K	2.2%	Form 4
Feb 18	Paul K. Audhya Chief Medical Officer	SoldNo plan	1,163	$15.00	17K	0.9%	Form 4
Feb 18	Christopher Yea Chief Development Officer	SoldNo plan	1,109	$15.00	17K	0.5%	Form 4
Feb 18	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	1,038	$15.00	16K	0.2%	Form 4
Feb 12	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	3,354	$15.70	53K	0.8%	Form 4
Dec 8, 2025	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	7,294	$16.51	120K	1.7%	Form 4
Nov 24, 2025	Nicole Sweeny Chief Commercial Officer	SoldNo plan	3,813	$13.45	51K	8.8%	Form 4
Nov 24, 2025	Paul K. Audhya Chief Medical Officer	SoldNo plan	5,296	$13.45	71K	3.9%	Form 4
Nov 24, 2025	Brian Piekos Chief Financial Officer	SoldNo plan	4,471	$13.45	60K	30%	Form 4
Nov 24, 2025	Christopher Yea Chief Development Officer	SoldNo plan	4,331	$13.45	58K	1.9%	Form 4
Nov 24, 2025	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	10,940	$13.45	147K	2.6%	Form 4
Nov 18, 2025	Paul K. Audhya Chief Medical Officer	SoldNo plan	3,075	$14.48	45K	2.4%	Form 4
Nov 18, 2025	Christopher Yea Chief Development Officer	SoldNo plan	2,683	$14.48	39K	2.0%	Form 4
Nov 18, 2025	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	4,466	$14.48	65K	1.1%	Form 4
Nov 12, 2025	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	3,328	$11.55	38K	0.8%	Form 4
Sep 8, 2025	Benjamin L Palleiko Chief Executive Officer	SoldNo plan	7,294	$15.84	116K	1.8%	Form 4
Aug 25, 2025	Nicole Sweeny Chief Commercial Officer	SoldNo plan	1,480	$13.42	20K	4.4%	Form 4

May 27No plan
Christopher Yea
Chief Development Officer · sold 33,800 at $26.78
905K
13% of stake
May 26No plan
Paul K. Audhya
Chief Medical Officer · sold 2,239 at $26.78
60K
1.5% of stake
May 26No plan
Nicole Sweeny
Chief Commercial Officer · sold 1,489 at $26.78
40K
2.4% of stake
May 26No plan
Christopher Yea
Chief Development Officer · sold 1,966 at $26.78
53K
0.8% of stake
May 22No plan
Paul K. Audhya
Chief Medical Officer · sold 2,685 at $26.78
72K
1.8% of stake
May 22No plan
Nicole Sweeny
Chief Commercial Officer · sold 1,861 at $26.78
50K
3.2% of stake
May 22No plan
Brian Piekos
Chief Financial Officer · sold 1,489 at $26.78
40K
6.4% of stake
May 22No plan
Christopher Yea
Chief Development Officer · sold 2,358 at $26.78
63K
1.0% of stake
May 22No plan
Benjamin L Palleiko
Chief Executive Officer · sold 10,926 at $26.78
293K
2.2% of stake
May 18No plan
Paul K. Audhya
Chief Medical Officer · sold 1,032 at $26.76
28K
0.7% of stake
May 18No plan
Christopher Yea
Chief Development Officer · sold 1,108 at $26.76
30K
0.5% of stake
May 18No plan
Benjamin L Palleiko
Chief Executive Officer · sold 1,129 at $26.76
30K
0.2% of stake
May 12No plan
Benjamin L Palleiko
Chief Executive Officer · sold 3,322 at $26.71
89K
0.7% of stake
Apr 17No plan
Paul K. Audhya
Chief Medical Officer · sold 2,686 at $20.22
54K
1.8% of stake
Apr 17No plan
Nicole Sweeny
Chief Commercial Officer · sold 1,862 at $20.22
38K
3.5% of stake
Apr 17No plan
Brian Piekos
Chief Financial Officer · sold 1,862 at $20.22
38K
9.3% of stake
Apr 17No plan
Benjamin L Palleiko
Chief Executive Officer · sold 9,550 at $20.22
193K
2.0% of stake
Mar 25 – 26No plan
Venrock Healthcare Capital Partners EG, L.p.
Large holder · sold 214,631 at avg $17.20
$3.69M
4.0% of stake
Mar 9No plan
Benjamin L Palleiko
Chief Executive Officer · sold 6,693 at $16.08
108K
1.5% of stake
Feb 23No plan
Paul K. Audhya
Chief Medical Officer · sold 5,354 at $15.57
83K
3.7% of stake
Feb 23No plan
Nicole Sweeny
Chief Commercial Officer · sold 3,975 at $15.57
62K
7.8% of stake
Feb 23No plan
Brian Piekos
Chief Financial Officer · sold 1,767 at $15.57
28K
11% of stake
Feb 23No plan
Christopher Yea
Chief Development Officer · sold 4,347 at $15.57
68K
1.9% of stake
Feb 23No plan
Benjamin L Palleiko
Chief Executive Officer · sold 10,034 at $15.57
156K
2.2% of stake
Feb 18No plan
Paul K. Audhya
Chief Medical Officer · sold 1,163 at $15.00
17K
0.9% of stake
Feb 18No plan
Christopher Yea
Chief Development Officer · sold 1,109 at $15.00
17K
0.5% of stake
Feb 18No plan
Benjamin L Palleiko
Chief Executive Officer · sold 1,038 at $15.00
16K
0.2% of stake
Feb 12No plan
Benjamin L Palleiko
Chief Executive Officer · sold 3,354 at $15.70
53K
0.8% of stake
Dec 8, 2025No plan
Benjamin L Palleiko
Chief Executive Officer · sold 7,294 at $16.51
120K
1.7% of stake
Nov 24, 2025No plan
Nicole Sweeny
Chief Commercial Officer · sold 3,813 at $13.45
51K
8.8% of stake
Nov 24, 2025No plan
Paul K. Audhya
Chief Medical Officer · sold 5,296 at $13.45
71K
3.9% of stake
Nov 24, 2025No plan
Brian Piekos
Chief Financial Officer · sold 4,471 at $13.45
60K
30% of stake
Nov 24, 2025No plan
Christopher Yea
Chief Development Officer · sold 4,331 at $13.45
58K
1.9% of stake
Nov 24, 2025No plan
Benjamin L Palleiko
Chief Executive Officer · sold 10,940 at $13.45
147K
2.6% of stake
Nov 18, 2025No plan
Paul K. Audhya
Chief Medical Officer · sold 3,075 at $14.48
45K
2.4% of stake
Nov 18, 2025No plan
Christopher Yea
Chief Development Officer · sold 2,683 at $14.48
39K
2.0% of stake
Nov 18, 2025No plan
Benjamin L Palleiko
Chief Executive Officer · sold 4,466 at $14.48
65K
1.1% of stake
Nov 12, 2025No plan
Benjamin L Palleiko
Chief Executive Officer · sold 3,328 at $11.55
38K
0.8% of stake
Sep 8, 2025No plan
Benjamin L Palleiko
Chief Executive Officer · sold 7,294 at $15.84
116K
1.8% of stake
Aug 25, 2025No plan
Nicole Sweeny
Chief Commercial Officer · sold 1,480 at $13.42
20K
4.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KALV, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KALV

CompareIntrinsic value

XOMAXOMA Corporation

€0.05-3.60%64

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

SPROSpero Therapeutics Inc.

$1.07+2.88%63

GOSSGossamer Bio Inc.

$9.40+1.29%10

SIGASiga Technologies Inc.

$3.15+1.29%20

QTTBQ32 Bio Inc.

$8.97+2.40%60

TNGXTango Therapeutics Inc.

$23.18+0.04%40

Held by ETFs

KALV is in 3 US ETFs. The largest of them, with KALV's weight in each:

Spot a number that looks wrong? Check it in KALV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KALV

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.